Relay Therapeutics Inc. (NASDAQ:RLAY) recently released interim data from their ongoing first-in-human study, ReDiscover, which is evaluating RLY-2608 in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer. The results were encouraging, with patients demonstrating clinically meaningful progression-free survival (PFS) when treated with RLY-2608 in combination with fulvestrant.
Key Takeaways:
- Median PFS of 9.2 months: This was observed across all mutations, with an even higher median PFS of 10.3 months in patients with kinase mutations.
- Clinical benefit rate (CBR) of 57%: This indicates that over half of the evaluable patients experienced complete response, partial response, or stable disease for at least 24 weeks.
- Objective response rate (ORR) of 33%: Among patients with measurable disease, one-third achieved a partial response.
- Tumor reductions in 73% of patients: This further highlights the potential efficacy of RLY-2608 in shrinking tumors.
- Favorable safety profile: RLY-2608 + fulvestrant was generally well tolerated.
These interim results suggest that RLY-2608 could be a promising new treatment option for patients with PI3Kα-mutated breast cancer. The company plans to continue the ReDiscover study and is also exploring the regulatory path for lirafugratinib, another drug in its pipeline.
Market Reaction:
Investors responded positively to the news, with Relay Therapeutics’ stock price surging over 50% on the day of the announcement. This reflects the market’s optimism about the potential of RLY-2608 and its potential to address an unmet need in breast cancer treatment.
Looking Ahead:
Relay Therapeutics remains well-funded, with cash reserves expected to last into the second half of 2026. This gives the company ample runway to continue developing its pipeline of innovative cancer therapies. With promising early data for RLY-2608 and a clear regulatory strategy for lirafugratinib, Relay Therapeutics is positioned for continued growth and success in the years to come.
Disclaimer: This blog post is for informational purposes only and does not constitute investment advice. Investing in the stock market carries inherent risks. It is crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.
